Aspira Pathlab & Diagnostics Ltd shares jump 3.06% as SEBI disclosure for Jay Arvind Bhanushali received
Why did Aspira Pathlab & Diagnostics Ltd shares jump today?
Aspira Pathlab & Diagnostics Ltd shares saw significant positive movement on Monday, rising 3.06% to reach a current price of ₹134.0 around 12:32 PM. This upward trend in the stock's performance indicates strong investor interest during the trading session.
The primary catalyst for this rally was a regulatory disclosure made to the stock exchanges. The company announced that it had received a filing under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. This disclosure was submitted by Jay Arvind Bhanushali, an individual noted as belonging to the promoter/promoter group of the company.
The details from the disclosure show that Mr. Bhanushali acquired 1,424 equity shares of Aspira Pathlab. While this represents a very small fraction (approximately 0.013%) of the company's total share capital, the acquisition by a person within the promoter group is often viewed positively by the market. It can signal the promoter's continued confidence in the company's future prospects, which likely boosted investor sentiment and contributed to the share price increase.
What does Aspira Pathlab & Diagnostics Ltd do?
Aspira Pathlab & Diagnostics Ltd is a publicly listed company, as indicated by its reference to the BSE LIMITED and its scrip code 540788. The company's shares are traded on the stock exchange, subject to regulatory disclosures under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
The company's equity shares are held by various shareholders, including members of the Promoter/Promoter group. A recent transaction involved the acquisition of 1424 equity shares, representing a 0.013% stake in the company, by an individual who is part of the Promoter/Promoter group.
Aspira Pathlab & Diagnostics Ltd Financials
In CroresAspira Pathlab & Diagnostics Ltd saw a revenue decline from ₹6.52 crores in March 2026 to ₹6.17 crores in June 2026, representing a quarter-over-quarter decrease. Concurrently, the company's net loss significantly improved, narrowing from ₹0.69 crores to just ₹0.04 crores during the same period. While top-line growth turned negative, the notable reduction in losses indicates a positive trend in operational efficiency or cost management, moving the company closer to a breakeven point.
Aspira Pathlab & Diagnostics Ltd Shareholding Pattern
Promoter holding stands at 46.58% of the total share capital. Foreign Institutional Investors (FIIs) hold 0.0% stake in the company, while Domestic Institutional Investors (DIIs) hold 0.0%. Public shareholders hold the remaining 53.41% stake in Aspira Pathlab & Diagnostics Ltd.
Aspira Pathlab & Diagnostics Ltd FAQs
Q: Why did Aspira shares jump 3.06% today?
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Aspira Pathlab & Diagnostics Ltd?
As per the latest data, promoters hold 46.58% stake in Aspira Pathlab & Diagnostics Ltd, while FII holding stands at 0.0%. Domestic institutional investors hold 0.0%, and public shareholders account for 53.41% of the equity.
Q: What is the current stock price of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd shares are currently trading at ₹134.0, recording a gain of 3.06% from the previous close.
Q: What is the market capitalization of Aspira Pathlab & Diagnostics Ltd?
The company currently has a market capitalization of ₹137.93 crore, reflecting its valuation in the Indian equity market.